News Archive

April 2020

• Ad-hoc Release Apr 28, 2020

  Novartis maintains strong operational performance in Q1, confirms FY 2020 guidance at this time, and advances a broad range of efforts to support the global response to COVID-19

    Q1 2020 net sales from continuing operations1 grew 13% (cc2, +11% USD) with double digit growth (cc) in Innovative Medicines and Sandoz: Key growth drivers include Entresto USD 569…
• Ad-hoc Release Apr 28, 2020

  Novartis setzt im 1. Quartal die starke operative Performance fort, bestätigt derzeit die Prognose 2020 und fördert verschiedenste Aktivitäten, um globale Massnahmen gegen COVID-19 zu unterstützen

  Der Nettoumsatz der fortzuführenden Geschäftsbereiche1 steigt im ersten Quartal 2020 um 13% (kWk2, +11% USD) mit zweistelligen Zuwächsen (kWk) bei Innovative Medicines und Sandoz: Zu den…
• Ad-hoc Release Apr 28, 2020

  Novartis conserve une forte performance opérationnelle au 1er trimestre, confirme à ce stade les prévisions pour 2020 et fournit de grands efforts pour contribuer à la réponse mondiale au Covid-19

  Au 1er trimestre 2020, chiffre d’affaires net des activités poursuivies1 en hausse de 13% (tcc2, +11% USD) avec une croissance à deux chiffres (tcc) d’Innovative Medicines et de Sandoz: Les…
• Press Release Apr 22, 2020

  Novartis announces data showing Jakavi® (ruxolitinib) more effective than best available therapy in acute graft-versus-host disease

  Data from Phase III REACH2 study, published in The New England Journal of Medicine, demonstrate Jakavi can improve outcomes for patients with acute graft-versus-host disease (GvHD) who do not respond…
• Press Release Apr 22, 2020

  Novartis Kymriah® receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma

  If approved, relapsed or refractory (r/r) follicular lymphoma would become the third B-cell malignancy indication for Kymriah, joining approvals in children and young adults with r/r ALL, and adults…
• Press Release Apr 21, 2020

  AveXis Community Statement on the Coronavirus Disease (COVID-19)

  Dear SMA Community, Like many organizations across the United States and around the world, AveXis is closely monitoring the coronavirus disease (COVID-19) and its impact on patients, the SMA…
• Press Release Apr 21, 2020

  Novartis announces new Mayzent® (siponimod) data show sustained effect in delaying disability for up to five years in patients with secondary progressive multiple sclerosis (SPMS)

  New long-term data from EXPAND show patients with SPMS continuously treated with Mayzent® (siponimod) experienced lower risk of disability progression and cognitive decline than patients who delayed…
• Press Release Apr 20, 2020

  Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients

  Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease Trial…
• Press Release Apr 20, 2020

  Novartis acquires Amblyotech, pursuing novel digital therapy for children and adult patients with “lazy eye”

  Technology has potential to reimagine treatment for amblyopia (“lazy eye”), a leading cause of vision loss in children and young adults1Acquisition expands the Novartis refractive disorder pipeline…
• Press Release Apr 16, 2020

  Novartis announces data in Neurology reinforcing the real-world and long-term effectiveness and safety of Aimovig® as a preventive treatment across the full spectrum of migraine

  Real-world evidence supports benefits seen in Aimovig clinical trials  Open-label data highlight long-term efficacy and safety profile of Aimovig in episodic and chronic migraine Post-hoc…
• Press Release Apr 02, 2020

  Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program

  New clinical trial to evaluate Jakavi® (ruxolitinib) in patients with COVID-19 associated cytokine storm  Cytokine storm is a type of severe immune overreaction that can result from coronavirus…
• Ad-hoc Release Apr 02, 2020

  Novartis announces mutual agreement to terminate sale of Sandoz US generic oral solids, dermatology portfolio to Aurobindo

  Basel, April 2, 2020 – Novartis today announced the mutual agreement with Aurobindo Pharma USA Inc. to terminate the agreement to sell the Sandoz US generic oral solids and dermatology businesses to…